Drug reference

olipudase alfa

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 1412, 1413

Review source pages for extracted sections and age labels.

Overview

Names and pronunciation

(oh-LIP-ue-dase AL-fa) Xenpozyme

PDF page 1412

Functional class

Func. class.: Enzyme

PDF page 1412

Uses

USES: Noncentral CNS effects of acid sphingomyelinase deficiency (ASMD)

PDF page 1412

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES ASMD during dose escalation and maintenance phase Adult: IV 0.1 mg/kg/dose initially, titrate dose q2wk: 0.3 mg/kg/dose on wk 2 and 4, 0.6 mg/kg/dose on wk 6 and 8, 1 mg/ kg/dose on wk 10, 2 mg/kg/dose on wk 12, and 3 mg/kg/dose on wk 14; mainte- nance is 3 mg/kg/dose q2wk Infant/child/adolescent: IV 0.03 mg/kg/ dose initially, titrate q2wk: 0.1 mg/kg/dose on wk 2, 0.3 mg/kg/dose on wk 4 and 6, 0.6 mg/kg/dose on wk 8 and 10, 1 mg/kg/ dose on wk 12, 2 mg/kg/dose on wk 14, and 3 mg/kg/dose on wk 16; maintenance is 3 mg/kg/dose q2wk Neonate: IV 0.03 mg/kg/dose initially, titrate q2wk: 0.1 mg/kg/dose on wk 2, 0.3 mg/kg/dose on wk 4 and 6, 0.6 mg/kg/dose on wk 8 and 10, 1 mg/kg/dose, on wk 12, 2 mg/kg/dose, on wk 14, 3 mg/kg/dose on wk 16; maintenance 3 mg/kg/dose q2wk

PDF pages 1412, 1413

Available forms

Available forms: Powder for injection 20 mg

PDF page 1413

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Loading InternPractice…